An open-label, non-randomized study to evaluate the effect of PEGASYS [peginterferon alfa-2a] on HBV-DNA [hepatitis B virus-DNA] in patients with HBeAG-negative [hepatitis B e antigen-negative] chronic hepatitis B infection.
Phase of Trial: Phase IV
Latest Information Update: 10 Oct 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 26 Jun 2007 Status changed from in progress
- 08 Jun 2006 New trial record.